In 
IDC MarketScape has announced Tata Consultancy Services (TCS) leads in worldwide Life Science Manufacturing and Supply Chain ITO. Among the attributes cited in the report, “IDC MarketScape: Worldwide Life Science Manufacturing and Supply Chain ITO 2013 Vendor Assessment,” TCS was lauded for its overall capability and extensive experience in working with global life science companies across all three sections of the industry: pharmaceutical, biotech, and medical devices.
The report evaluated the 12 leading IT vendors that serve the life science manufacturing and supply chain space, across a number of capability and strategy measures such as Offering Roadmap, Portfolio Strategy, Customer Base, Engagement Capability, Pricing Model, Investment, Growth Strategy, etc. IDC MarketScape criteria selection, weightings and vendor scores represent well-researched IDC judgment about the market and vendors through structured discussions, surveys and interviews with market leaders, participant buyers and end users.
“In the current market conditions, there is a strong demand from Life Sciences companies for skilled IT outsourcing (ITO) partners that have significant domain depth and experience” said Eric Newmark, Program Director, IDC Health Insights, Business Systems Strategies Program. “TCS has demonstrated its expertise and innovation through its extensive work with life sciences companies in the Manufacturing and Supply Chain market. TCS’ exceptional technical skills, coupled with the overall value that the company consistently delivers to its global Life Sciences clients, make it an established leader in the field.”
“Our continued leadership in the Life Sciences manufacturing and supply chain market is a testament to the unparalleled value we bring to our customers,” said Debashis Ghosh, President of Life Sciences, Manufacturing and Energy, TCS. “Our strategy is to enable life sciences companies to use technology effectively to optimize manufacturing operations and adopt emerging supply chain practices which will result in a more holistic, patient-centric healthcare ecosystem. This, coupled with a strong global footprint and a continuous focus on innovation, ensures that we are a partner of choice for life sciences companies worldwide.”
Add new comment